.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Citi
Moodys
Baxter
Daiichi Sankyo
Fish and Richardson
Healthtrust
Cerilliant
US Department of Justice
AstraZeneca

Generated: December 18, 2017

DrugPatentWatch Database Preview

Kowa Co Company Profile

« Back to Dashboard

What is the competitive landscape for KOWA CO, and what generic alternatives to KOWA CO drugs are available?

KOWA CO has one approved drug.

There are four US patents protecting KOWA CO drugs.

There are fifty-five patent family members on KOWA CO drugs in nineteen countries.

Summary for Kowa Co

International Patents:55
US Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-003Aug 3, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-001Aug 3, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-001Aug 3, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-003Aug 3, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-003Aug 3, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-003Aug 3, 2009ABRXYesYes► Subscribe► SubscribeYY► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-002Aug 3, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-001Aug 3, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-002Aug 3, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-002Aug 3, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Kowa Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-003Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-002Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-001Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-002Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-003Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-003Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-002Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-001Aug 3, 2009► Subscribe► Subscribe
Kowa CoLIVALOpitavastatin calciumTABLET;ORAL022363-001Aug 3, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for KOWA CO drugs

Drugname Dosage Strength Tradename Submissiondate
pitavastatin calciumTablets1 mg, 2 mg, and 4 mgLIVALO8/5/2013

Non-Orange Book Patents for Kowa Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,872,130 Quinoline type mevalonoactones► Subscribe
5,011,930 Quinoline type mevalonolactones► Subscribe
8,853,405Crystalline forms of pitavastatin calcium► Subscribe
7,776,881Hyperlipemia therapeutic agent► Subscribe
5,854,259 Quinoline type mevalonolactones► Subscribe
5,185,328 Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis► Subscribe
5,102,888 Quinoline type mevalonolactones useful for treating hyperlipidemia and related diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Kowa Co Drugs

Country Document Number Estimated Expiration
Japan2015172086► Subscribe
Taiwan200420541► Subscribe
China101219992► Subscribe
Japan2014198743► Subscribe
Austria460164► Subscribe
Austria114645► Subscribe
Japan5445713► Subscribe
Japan2006518354► Subscribe
Taiwan201514149► Subscribe
Canada2785954► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
Julphar
Baxter
Chubb
Accenture
AstraZeneca
Novartis
Federal Trade Commission
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot